Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 6 of 30
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
NCT02491099
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans
NCT02781519
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
NCT01730781
Reversal of Lipid-Induced Insulin Resistance
NCT02193295
Breast Cancer Screening Decision Aid
NCT07515846
A Trial to Reduce Inappropriate Prescribing to Older Adults Visiting the Emergency Department
NCT07146763
BHV-7000 Responsive Neurostimulation System (RNS) Study
NCT07125261
Impact of a Community Health Worker Strategy on Produce Prescription Program Uptake Among People With Diabetes
NCT06401668
Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis
NCT05309616
An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.
NCT07062848
Community Health Equity Accelerator (CHEA) Pediatric Asthma Intervention
NCT06507943
Targeting Fronto-Striatal Neural Circuitry Using Repetitive Transcranial Magnetic Stimulation to Reduce Irritability
NCT07678060
Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs
NCT06411223
Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study
NCT06111768
Apremilast for Alcohol Use Disorder Treatment in Women and Men
NCT06324435
Impact of Family-Centered Care for Intimate Partner Violence (IPV)
NCT06071299
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
NCT06028932
Oral Dronabinol-HIV
NCT06034314
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
NCT05223829
Effects of Repeated Psilocybin Dosing in OCD
NCT05370911
Pain Care at Home to Amplify Function (Pain CHAMP)
NCT05333341
Buprenorphine Integration Research and Community Health
NCT05668780
FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea
NCT05364008
Potential Impact of Menthol Ban in Cigarettes and E-cigarettes
NCT05259566
Dissemination and Implementation of the Bright Bodies Intervention for Childhood Obesity
NCT05595161
The DISCOVER INOCA Prospective Multi-center Registry
NCT05288361
Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations
NCT05286879
Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)
NCT04605081
Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)
NCT04599504
Novel physIologiC prEdictors of Positive Airway Pressure Effectiveness
NCT05067088
SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs
NCT04710563
Neuro-immune Interactome in Parkinson's Disease
NCT07026929
Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support
NCT04309565
AB154 Combined With AB122 for Recurrent Glioblastoma
NCT04656535
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
NCT04711915
Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients
NCT05286242
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
NCT04699123
Exploring Outcomes and Characteristics of Myasthenia Gravis 2
NCT06002945
Behavior Therapy for Irritability in Autism
NCT04654260
A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants
NCT04419857
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
NCT04495257
Physician-Modified Fenestrated and Branched Aortic Endografting for TAAA
NCT02989948
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
NCT04251416
Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
NCT03991962
Transcranial Magnetic Stimulation on Neural and Behavioral Facets of Social Cognition in Autism Spectrum Disorder
NCT04242355
Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy
NCT03670056
Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking?
NCT03588754
CB1R in Synthetic Psychoactive Cannabinoids
NCT03539575
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
NCT03456843
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
NCT03554174
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Yale University pipeline card: 1,492 registered trials from official public datasets.Report a data error.